Advent International announced that its portfolio company Grupo Biotoscana, a specialty pharmaceutical company in Latin America, priced its initial public offering at R$26.50 per share on Brazil’s B3 Exchange, generating gross proceeds of US$375.2m.
- Since Advent’s initial investment in 2011, Grupo Biotoscana has experienced significant growth and strengthened its presence in the major Latin American markets of Brazil and Argentina
- Company has consummated strategic acquisitions and successful integrations of Biotoscana, United Medical and Laboratorio LKM
- Advent retains significant equity stake and Board representation
BOSTON, MA and MONTEVIDEO, URUGUAY, August 22, 2017 – Advent International, one of the largest and most experienced global private equity investors, today announced that its portfolio company, Grupo Biotoscana (“GBT”), a leading specialty pharmaceutical company in Latin America, priced its initial public offering on July 25, 2017 at R$26.50 per share, generating gross proceeds of US$375.2 million. The Company is listed on Brazil’s B3 Exchange under the trading symbol “GBIO33”. Advent has retained a significant equity stake in GBT and will maintain a presence on the Company’s Board of Directors.
“Last month, we began our next phase of growth as a public company,” said Mr. Mariano Garcia-Valino, CEO of GBT. “We are very excited for this next step in our evolution as we continue to work with Advent on our expansion throughout Latin America. With the help of Advent’s dedicated support and leadership, we have built a portfolio of high-technology specialty pharmaceuticals, focused mainly on infectious diseases, oncology and oncohematology, special treatments, immunology and inflammation and orphan/rare diseases, among others, and have grown our product offering by nearly 35% over the past six years.”
GBT is one of the few Latin American integrated pharmaceutical companies engaged primarily in the development, manufacturing and commercialization of branded specialty pharmaceutical products throughout the region. GBT has an established presence in all major Latin American markets, with operations in Brazil, Argentina, Colombia, Bolivia, Chile, Ecuador, Mexico, Paraguay, Peru and Uruguay.
“We are pleased to continue to work with Mariano and his skilled management team as GBT embarks on its journey as a publicly traded company,” added Juan Pablo Zucchini, Managing Partner in Advent’s São Paulo office. “In our role on the Board of Directors, we look forward to maintaining our support of GBT’s positive momentum. Over the duration of our partnership, GBT has shown tremendous actualized growth and we are confident in GBT’s continued success moving forward.”
“Through a six-year transformation process that began with the acquisition of Biotoscana in Colombia in 2011, we have successfully grown GBT through the strategic acquisition and integration of three strong, complementary businesses: Biotoscana, United Medical and Laboratorio LKM. We are proud to have supported GBT as it became the first Latin American specialty pharmaceutical company with a truly pan-regional presence, and we look forward to continued success in the future,” said Mauricio Salgar, Managing Director in Advent’s Bogotá office.